Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizuma...
Q3 2026
Aug 13, 2026
Q2 2026
May 15, 2026
Q1 2026
Feb 17, 2026
FY 2025
Dec 19, 2025
Q4 2025
